- For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoriatic disease and ankylosing spondylitis
- The abstract presented at the World Congress of Dermatology in Milan shows the long-term efficacy and safety of Cosentyx in multiple manifestations of psoriatic disease including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis
- Proven efficacy of treatments in persistent manifestations of nails, scalp and palmoplantar psoriasis is a specific concern for patients as these are significantly reducing the quality of life and are impacting up to 9 out of 10 psoriasis patients ,
- Additional new 5 year data with Cosentyx confirmed low immunogenicity with rates year-over-year consistently below 1% in patients with moderate to severe plaque psoriasis
- Cosentyx is reimagining patient care with a wealth of research from 100 studies and has been proven to offer clear or almost clear skin in 8 out of 10 patients within 16 weeks of treatment. Data presented in 2017 showed that PASI 90 and PASI 100 response rates were nearly 100% maintained with Cosentyx from Year 1 to Year 5 in patients with moderate-to-severe plaque psoriasis
Basel, June 17, 2019 - "Today, patients and doctors are concerned about the manifestations of psoriatic disease beyond skin plaques which are painful and often lead to irreversible damage", said Richard Langley, Professor of Dermatology, Dalhousie University, Halifax, Nova Scotia, Canada. "These data across multiple manifestations of psoriatic disease including persistent manifestations, psoriatic arthritis as well as ankylosing spondylitis provide much needed, additional guidance for prescribing dermatologists who want to treat their patient in a comprehensive way."
The abstract "Secukinumab provides comprehensive long-term treatment across multiple manifestations of psoriatic disease" (World Congress of Dermatology in Milan, 10-15 June 2019) is presenting the long-term efficacy and safety of secukinumab in multiple manifestations of psoriatic disease including, moderate-to-severe plaque-type, nail and palmoplantar psoriasis; psoriatic arthritis and ankylosing spondylitis. Data are derived from key Phase 3, randomised, double-blind trials of secukinumab (SCULPTURE, ERASURE/FIXTURE, TRANSFIGURE, GESTURE, FUTURE 2 and MEASURE 2) in a total of 1,872 patients.
The abstract "Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients over 5 years" (World Congress of Dermatology in Milan, 10-15 June 2019) investigated the immunogenicity of secukinumab treatment up to 5 years in two phase III extension studies (CAIN457A2304 and CAIN457A2307) in patients with moderate to severe plaque psoriasis. In total, 1821 patients entered the extension studies.